dr. reddys laboratories ltd - RDY

RDY

Close Chg Chg %
13.97 0.12 0.86%

Closed Market

14.09

+0.12 (0.86%)

Volume: 2.90M

Last Updated:

Feb 6, 2026, 3:59 PM EDT

Company Overview: dr. reddys laboratories ltd - RDY

RDY Key Data

Open

$13.97

Day Range

13.84 - 14.10

52 Week Range

12.28 - 16.17

Market Cap

$11.65B

Shares Outstanding

832.38M

Public Float

832.36M

Beta

0.35

Rev. Per Employee

N/A

P/E Ratio

17.92

EPS

$0.78

Yield

51.18%

Dividend

$0.07

EX-DIVIDEND DATE

Jul 25, 2025

SHORT INTEREST

N/A

AVERAGE VOLUME

2.08M

 

RDY Performance

1 Week
 
4.92%
 
1 Month
 
5.07%
 
3 Months
 
4.61%
 
1 Year
 
1.37%
 
5 Years
 
7.33%
 

RDY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 38
Full Ratings ➔

About dr. reddys laboratories ltd - RDY

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment focuses on manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

RDY At a Glance

Dr. Reddy's Laboratories Ltd.
Door No. 8-2-337
Hyderabad, Telangana 500034
Phone 91-40-49002900 Revenue 3.85B
Industry Pharmaceuticals: Major Net Income 668.79M
Sector Health Technology 2025 Sales Growth 14.179%
Fiscal Year-end 03 / 2026 Employees 27,811
View SEC Filings

RDY Valuation

P/E Current 17.922
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 16.428
Price to Sales Ratio 2.858
Price to Book Ratio 2.822
Price to Cash Flow Ratio 20.08
Enterprise Value to EBITDA 10.663
Enterprise Value to Sales 2.835
Total Debt to Enterprise Value 0.05

RDY Efficiency

Revenue/Employee 138,447.282
Income Per Employee 24,047.685
Receivables Turnover 3.349
Total Asset Turnover 0.739

RDY Liquidity

Current Ratio 1.918
Quick Ratio 1.373
Cash Ratio 0.444

RDY Profitability

Gross Margin 55.441
Operating Margin 21.35
Pretax Margin 23.52
Net Margin 17.37
Return on Assets 12.844
Return on Equity 18.413
Return on Total Capital 15.037
Return on Invested Capital 18.007

RDY Capital Structure

Total Debt to Total Equity 14.027
Total Debt to Total Capital 12.302
Total Debt to Total Assets 9.486
Long-Term Debt to Equity 2.359
Long-Term Debt to Total Capital 2.069
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Dr. Reddys Laboratories Ltd - RDY

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
2.88B 3.06B 3.37B 3.85B
Sales Growth
+12.60% +6.35% +10.20% +14.18%
Cost of Goods Sold (COGS) incl D&A
1.43B 1.41B 1.49B 1.72B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
158.70M 157.27M 179.27M 201.76M
Depreciation
109.42M 107.22M 115.68M 124.25M
Amortization of Intangibles
49.29M 50.04M 63.60M 77.51M
COGS Growth
+13.91% -1.79% +6.15% +14.86%
Gross Income
1.44B 1.65B 1.88B 2.13B
Gross Income Growth
+11.33% +14.41% +13.64% +13.64%
Gross Profit Margin
+50.21% +54.02% +55.70% +55.44%
2022 2023 2024 2025 5-year trend
SG&A Expense
984.72M 1.01B 1.11B 1.32B
Research & Development
220.28M 228.55M 262.14M 307.92M
Other SG&A
764.44M 778.09M 848.89M 1.01B
SGA Growth
+13.42% +2.23% +10.37% +18.49%
Other Operating Expense
(2.76M) (3.48M) (4.08M) (3.82M)
Unusual Expense
101.50M 8.70M 36.24K 20.02M
EBIT after Unusual Expense
361.33M 641.17M 771.50M 802.02M
Non Operating Income/Expense
75.59M 123.31M 115.55M 137.06M
Non-Operating Interest Income
12.95M 14.69M 27.52M 31.66M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
12.86M 17.77M 20.67M 33.46M
Interest Expense Growth
-1.59% +38.22% +16.29% +61.89%
Gross Interest Expense
18.51M 24.98M 31.71M 47.86M
Interest Capitalized
5.65M 7.21M 11.04M 14.39M
Pretax Income
424.07M 746.71M 866.39M 905.62M
Pretax Income Growth
+21.40% +76.08% +16.03% +4.53%
Pretax Margin
+14.74% +24.40% +25.69% +23.52%
Income Tax
117.17M 190.42M 195.52M 231.10M
Income Tax - Current - Domestic
56.10M 109.12M 167.59M 211.82M
Income Tax - Current - Foreign
29.94M 50.90M 67.45M 55.26M
Income Tax - Deferred - Domestic
29.06M 48.43M 11.69M (12.70M)
Income Tax - Deferred - Foreign
2.07M (18.03M) (51.22M) (23.28M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
316.33M 560.90M 672.64M 677.08M
Minority Interest Expense
- - - 8.29M
-
Net Income
316.33M 560.90M 672.64M 668.79M
Net Income Growth
+36.24% +77.31% +19.92% -0.57%
Net Margin Growth
+10.99% +18.33% +19.95% +17.37%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
316.33M 560.90M 672.64M 668.79M
Preferred Dividends
- - - -
-
Net Income Available to Common
316.33M 560.90M 672.64M 668.79M
EPS (Basic)
0.3814 0.6756 0.8085 0.8029
EPS (Basic) Growth
+36.21% +77.14% +19.67% -0.69%
Basic Shares Outstanding
829.41M 830.17M 831.97M 832.95M
EPS (Diluted)
0.3803 0.6742 0.807 0.8017
EPS (Diluted) Growth
+36.21% +77.28% +19.70% -0.66%
Diluted Shares Outstanding
831.69M 831.94M 833.54M 834.18M
EBITDA
621.53M 807.14M 950.82M 1.02B
EBITDA Growth
+2.94% +29.86% +17.80% +7.68%
EBITDA Margin
+21.60% +26.38% +28.20% +26.59%

Snapshot

Average Recommendation HOLD Average Target Price 14.404
Number of Ratings 38 Current Quarters Estimate 0.13
FY Report Date 03 / 2026 Current Year's Estimate 0.668
Last Quarter’s Earnings 0.158 Median PE on CY Estimate N/A
Year Ago Earnings 0.794 Next Fiscal Year Estimate 0.603
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 5 3 34 33
Mean Estimate 0.13 0.16 0.67 0.60
High Estimates 0.19 0.19 0.76 0.73
Low Estimate 0.10 0.15 0.47 0.48
Coefficient of Variance 30.88 14.45 8.77 10.82

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 14 14 12
OVERWEIGHT 2 2 2
HOLD 11 11 13
UNDERWEIGHT 4 5 6
SELL 7 7 6
MEAN Hold Hold Hold

Dr. Reddys Laboratories Ltd in the News